ImmuCell Sees Q2 $(0.20) Down From $(0.18) YoY; Product Sales $5.473M Up From $3.533M YoY
Portfolio Pulse from Benzinga Newsdesk
ImmuCell reported a Q2 loss of $(0.20) per share, down from $(0.18) per share year-over-year. However, product sales increased to $5.473 million from $3.533 million year-over-year.
August 13, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ImmuCell reported a Q2 loss of $(0.20) per share, which is a decline from $(0.18) per share year-over-year. Despite the increased loss, product sales rose significantly to $5.473 million from $3.533 million year-over-year.
The increased loss per share may concern investors, but the significant rise in product sales could offset some of the negative sentiment. The net impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100